HighTower Advisors’s Moleculin Biotech MBRX Stock Holding History

HighTower Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1	Closed	-$21K	–	3180
2020 Q4	$21K	Buy	+1	New	+$35.5K	﹤0.01%	2477

Other funds holding MBRX

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $21.3B AUM 44.31% 1-Year Est. Return

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

HighTower Advisors's MBRX Position: Q1 2021 in Review

HighTower Advisors sold out of Moleculin Biotech (MBRX) in Q1 2021, closing a stake of 1 share — an estimated $21K sold.

HighTower Advisors first reported a position in MBRX in Q4 2020 and held it in 1 quarter. The position peaked at $21K in Q4 2020. 18 funds tracked by Wall St. Rank hold MBRX as of Q1 2021.

HighTower Advisors reported no remaining Moleculin Biotech position as of Q1 2021 after selling out during the quarter.
HighTower Advisors sold 1 Moleculin Biotech share in Q1 2021, an estimated $21K.
HighTower Advisors first reported a position in Moleculin Biotech in Q4 2020 and held it in 1 quarter.
HighTower Advisors's Moleculin Biotech position peaked at $21K in Q4 2020.
18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2021.

Based on HighTower Advisors's 13F filing for Q1 2021, filed 10 May 2021.